Hims & Hers: Shortage Saga Brings Stupendous Risk-Reward
Anticipating a 35% CAGR in 2025, Hims & Hers is poised for substantial growth. Read why I maintain my strong buy rating on ...
Hims & Hers Health stock tanks after FDA says competitor Eli Lilly’s weight-loss drug shortage is over
The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...
For Hims & Hers Stock, GLP-1 Giveth and GLP-1 Taketh Away
Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.
TipRanks on MSN18h
HIMS Stock Rises 208% in a Year and Is Ready to Compete with the Big Guns
As a player in the growing telehealth sector, Hims & Hers Health ($HIMS) has grown significantly, driving its stock up over ...
Costco, Hims, Noom, and more: 6 companies that started hawking weight loss products this year
Exploding sales of prescription weight loss medications have catapulted Novo Nordisk (NVO) and Eli Lilly (LLY) to become the ...
Hims & Hers Health, Inc. (HIMS): A Bull Case Theory
We came across a bullish thesis on Hims & Hers Health, Inc. (HIMS) on La Newsletter de Momentum’s Substack by Mexican ...
These 2 Healthcare Stocks With Big Catalysts on the Horizon Can Make You Richer
Market-beating returns could be on the way for patient investors in these two up-and-coming healthcare growth stocks.
Is the soaring Hims & Hers stock a good investment?
Hims & Hers (NASDAQ: HIMS) stock has done well since the company went public a few years ago. It has soared by over 193% in ...
Fast Company6d
Hims & Hers Health stock tanks after FDA says competitor Eli Lilly’s weight-loss drug shortage is over
Thus, Hims & Hers contends that the FDA’s move doesn’t affect it at all and doesn’t preclude the compounding of GLP-1 drugs. “Products that are not essentially copies can continue to be ...